Biological
H5N1 Vaccine
H5N1 Vaccine is a biological therapy with 2 clinical trials. Historical success rate of 50.0%.
Total Trials
2
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
1(50%)
Phase Distribution
Ph phase_1
1
50%
Ph phase_2
1
50%
Phase Distribution
1
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 2Efficacy & side effects
1(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Completed(1)
Terminated(1)
Detailed Status
Completed1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
50.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (50.0%)
Phase 21 (50.0%)
Trials by Status
completed150%
terminated150%
Recent Activity
0 active trials
Showing 2 of 2
terminatedphase_2
Development of Immune Globulin Treatment for Avian Flu
NCT00383071
completedphase_1
Evaluating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Previously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Attenuated Influenza Vaccine
NCT01443663
Clinical Trials (2)
Showing 2 of 2 trials
NCT00383071Phase 2
Development of Immune Globulin Treatment for Avian Flu
NCT01443663Phase 1
Evaluating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Previously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Attenuated Influenza Vaccine
All 2 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 2